Molecular Vaccines From Prophylaxis to Therapy - Volume 2 /

This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clini...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Giese, Matthias (Επιμελητής έκδοσης)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Cham : Springer International Publishing : Imprint: Springer, 2014.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 02311nam a22004695i 4500
001 978-3-319-00978-0
003 DE-He213
005 20151204170725.0
007 cr nn 008mamaa
008 131107s2014 gw | s |||| 0|eng d
020 |a 9783319009780  |9 978-3-319-00978-0 
024 7 |a 10.1007/978-3-319-00978-0  |2 doi 
040 |d GrThAP 
050 4 |a RM281 
050 4 |a QR189-189.5 
072 7 |a MJCM  |2 bicssc 
072 7 |a MED044000  |2 bisacsh 
082 0 4 |a 615.372  |2 23 
245 1 0 |a Molecular Vaccines  |h [electronic resource] :  |b From Prophylaxis to Therapy - Volume 2 /  |c edited by Matthias Giese. 
264 1 |a Cham :  |b Springer International Publishing :  |b Imprint: Springer,  |c 2014. 
300 |a XXVIII, 870 p. 98 illus., 74 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Non-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration. 
520 |a This title discusses all aspects of non-infectious and non-cancer– so called NINC – vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application. 
650 0 |a Medicine. 
650 0 |a Immunology. 
650 0 |a Vaccines. 
650 0 |a Molecular biology. 
650 1 4 |a Biomedicine. 
650 2 4 |a Vaccine. 
650 2 4 |a Immunology. 
650 2 4 |a Molecular Medicine. 
700 1 |a Giese, Matthias.  |e editor. 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9783319009773 
856 4 0 |u http://dx.doi.org/10.1007/978-3-319-00978-0  |z Full Text via HEAL-Link 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642)